Arcadia Biosciences stock (US03020Q1058): Nasdaq listing stays under pressure

Arcadia Biosciences remains listed on Nasdaq under ticker RKDA, with the latest coverage pointing to a share price below $1 and softer Q1 revenue trends.

Arcadia Biosciences remained on Nasdaq under ticker RKDA on 06/01/2026, and recent coverage noted that the shares were still trading below $1 while investors focused on weaker first-quarter revenue trends. The stock was cited at $0.97 on 06/01/2026 in Germany-linked market coverage, and the U.S. home listing keeps the name on the radar for Nasdaq-based retail investors.

According to ad-hoc-news coverage indexed on 06/01/2026, the issue stayed on the market after earlier Q1 earnings commentary highlighted a loss and a revenue miss, while a separate market snapshot linked to the stock showed the same sub-$1 trading backdrop.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Arcadia Biosciences
• Sector/industry: Agricultural biotechnology
• Headquarters/country: Davis, United States
• Core markets: United States and selected international licensing markets
• Key revenue drivers: Seed traits, licensing, and product commercialization
• Home exchange/listing venue: Nasdaq (RKDA)
• Trading currency: USD

Arcadia Biosciences: core business model

Arcadia Biosciences develops agricultural traits and related products that are designed to improve crop performance and support licensing-based commercialization, with the business now centered on a narrower operating footprint than in earlier years.

What banks and research houses say about Arcadia Biosciences

No verified analyst coverage was identified at the time of publication.

The lack of a fresh bank note leaves the stock dependent on trading data, company updates, and any follow-through from earnings or corporate actions. For Nasdaq investors, that means the next documented catalyst is more likely to come from filings or results than from a price-target reset.

Conclusion

Arcadia Biosciences enters the new week with Nasdaq listing status intact, but the main market focus remains on the sub-$1 share price and the weaker Q1 backdrop highlighted in recent coverage. With no fresh analyst note identified, the next meaningful update for RKDA is likely to come from company reporting or another filing rather than from broker action.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.